Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics

No abstract is available for this paper.

• Publication year

  2009

• Venue

  AIDS (London)

• Publication date

  2009-11-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/QAD.0b013e32832ff1c0PMID 19898214PMCID PMC2904970
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictive Value of Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients Treated With an Interferon-Based Regimen Plus Ribavirin

  2007cited by this paper
• HCV kinetics, quasispecies, and clearance in treated HCV‐infected and HCV/HIV‐1‐coinfected patients with hemophilia

  2006cited by this paper
• Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.

  2006cited by this paper
• Pharmacodynamics of PEG‐IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders

  2006cited by this paper
• A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

  2006cited by this paper
• Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

  2006cited by this paper
• HCV natural history: the retrospective and prospective in perspective.

  2005cited by this paper
• Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy.

  2005cited by this paper
• HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.

  2005cited by this paper
• New kinetic models for the hepatitis C virus

  2005cited by this paper
• Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

  2004cited by this paper
• Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients

  2004cited by this paper
• Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

  2004cited by this paper
• Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

  2004cited by this paper
• Virus Dynamics and Immune Responses During Treatment in Patients Coinfected With Hepatitis C and HIV

  2004cited by this paper
• CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Metaanalysis of 3 Vanguard Studies

  2004cited by this paper
• Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000.

  2003cited by this paper
• Hepatitis C Virus-Rna Clearance in HIV-Coinfected Patients with Chronic Hepatitis C Treated with Pegylated Interferon plus Ribavirin

  2003cited by this paper
• Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients.

  2003cited by this paper
• Pharmacokinetics of Peginterferons

  2003cited by this paper
• Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection.

  2003cited by this paper
• Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

  2003cited by this paper
• Hepatotoxicity Associated with Antiretroviral Therapy Containing HIV-1 Protease Inhibitors

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Viral Dynamics and Pharmacokinetics of Peginterferon Alpha-2A and Peginterferon Alpha-2B in Naive Patients with Chronic Hepatitis C: A Randomized, Controlled Study

  2003cited by this paper
• Hepatitis C in the HIV-Infected Person

  2003cited by this paper
• Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b.

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Trends in Diseases Reported on U.S. Death Certificates That Mentioned HIV Infection, 1987‐1999

  2002cited by this paper
• Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

  2002cited by this paper
• Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections

  2002cited by this paper
• Hepatotoxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV: The Role of Hepatitis B and C Virus Infection

  2002cited by this paper
• Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.

  2001cited by this paper
• Hepatitis C virus infection in the United States.

  1999cited by this paper
• Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients

  1999cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998influential reference
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998influential reference
• 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. USPHS/IDSA Prevention of Opportunistic Infections Working Group. US Public Health Services/Infectious Diseases Society of America.

  1997cited by this paper
• USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations

  1995cited by this paper
• Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study.

  1994cited by this paper
• Increasing Hepatitis C Virus RNA Levels in Hemophiliacs: Relationship to Human Immunodeficiency Virus Infection and Liver Disease

  1994cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• PEGylated interferon displays differences in plasma clearance and bioavailability between male and female mice and between female immunocompetent C57Bl/6J and athymic nude mice.

  2015cites this paper
• Sex, Age, Race and Intervention Type in Clinical Studies of HIV Cure: A Systematic Review

  2015cites this paper
• Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype‐1 infected patients

  2014cites this paper
• Survival of HIV-positive individuals with hepatitis B and C infection in Michigan

  2013cites this paper
• Spread to CD 4 Immature Dendritic Cells and Limits HIV-1 Induces APOBEC 3 G , F , and A in α

  2013cites this paper
• IFN-α Induces APOBEC3G, F, and A in Immature Dendritic Cells and Limits HIV-1 Spread to CD4+ T Cells

  2013cites this paper
• IFN-a Induces APOBEC 3 G , F , and A in Immature Dendritic Cells and Limits HIV-1 Spread to CD 4 + T Cells

  2013cites this paper
• Racial Disparities in HIV and Liver Disease

  2012cites this paper
• Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B‐unfavorable genotype patients: Impaired viral kinetics and therapeutic response

  2012cites this paper
• Response to disease modifying therapies in African Americans with multiple sclerosis.

  2012cites this paper
• Analytical measurement of PEGylated molecules.

  2012cites this paper
• Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and Interleukin-28B

  2011cites this paper
• Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.

  2011cites this paper
• Very early prediction of response to HCV treatment with PEG‐IFN‐alfa‐2a and ribavirin in HIV/HCV‐coinfected patients

  2011cites this paper
• Early viral kinetics: a novel guide for optimal dosing frequency of pegylated interferon-α-2a in HIV/HCV-coinfected patients

  2011cites this paper
• Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management.

  2011cites this paper
• Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy

  2011cites this paper
• Interferon combination therapy for HIV/hepatitis C virus coinfection.

  2011cites this paper
• Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

  2010cites this paper
• Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa.

  2010cites this paper
• Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.

  2010cites this paper